Sana Biotechnology Inc SANA

$2.02 +0.01 (0.50%)

Valuation

Market cap
605,263,000
Revenue TTM
$0
Net income TTM
$-244,170,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
3,201,100
Avg volume
3,470,734
Day's range
$1.86 – $2.05
Shares out
299,635,000
Stochastic %K
21%
Beta
2.30
Analysts
Strong Buy
Price target
$9.86

Price

Company profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product,...

Show more

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Industry
Biotechnology
Sector
Healthcare
Phone
206 701 7914
Website
https://www.sana.com
Address
188 East Blaine Street, Suite 350, Seattle, United States

Latest news

Stocktwits

mirko_papuga Nov 16, 3:51 AM
$SANA Unrelated to SANA of the upcoming IND, but some interesting breakthroughs to what may be a root cause of diabetes, if the below is accurate, see the receptor on macrophages 'GPR18': https://www.news18.com/india/diabetes-breakthrough-treatment-immune-cell-off-switch-insulin-iit-kanpur-research-ws-el-10426327.html https://www.iitk.ac.in/scientists-discover-immune-cells-silence-insulin I have not reviewed it, but the paper, “Acute activation of Gq-signaling in pancreatic islet macrophages inhibits insulin secretion through AMPK-sphingolipid axis,” is published in the Journal of Clinical Investigation and is available at https://www.jci.org/articles/view/202344 .
1 replies
bubbaxyz Nov 16, 1:46 AM
$SANA acting as though its heading to penny status at this rate of decline.
2 replies
bonhommetwits Nov 13, 8:31 PM
$SANA Great price to pick up shares! Also, Imo, this would be a good candidate for a buyout. How about $VRTX?!
0 replies
BriOnH Nov 13, 7:27 PM 1 replies
BriOnH Nov 13, 4:56 PM
@mirko_papuga @JerryMalone32 I think I can speak for Jerry on this one, and even @Jjpratt19 , just as they could speak for me, and I hope you both chime in, apologies to either of you if I got this wrong, but there's no selling unless the science says otherwise. The science absolutely does not say otherwise. If you know biotech, you know how financing goes, its the name of the game. Seeing the constant posts in $ELDN and $SANA about financing worries; this is how it goes. It's unpleasant, it sucks, it is a worry, and fact of the matter, statistically chances are we will lose most of our investment investing in single biotech names. Compound that with falling knife price action, well sure it doesn't feel good. The reason most of us invested hasn't changed. We knew the financial risks going in. The science is what brought us here, and until that changes, short term price action doesn't change the thesis. These troll, bear, knife falling days suck. Still waiting for the cure day.
4 replies
ParkerTrades3393 Nov 13, 3:37 PM
$SANA brilliant idea— but unexecutable. Zero soon when they run out of money.
1 replies
ParkerTrades3393 Nov 13, 3:06 PM
$SANA how do they spend so much money every quarter dividing cells? I get that tech is expensive but 100m??? Common. How much is he CEO taking out?
1 replies
JRNY13 Nov 13, 2:42 PM
$SANA great technology. Lousy CEO
0 replies